PL00001：Preclinical evaluation of a dual sstr2 and integrin αvβ3-targeted heterodimer [68Ga]-NOTA-3PEG -TATE-RGD

PL00002：Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism

PL00003：Head-to-head comparison of 68 Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study

PL00004：Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin αvβ3

PL00005：68Ga-Pentixafor PET/CT for imaging of chemokine receptor-4 expression in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma: comparison to 18F-FDG PET/CT

PL00006：Chemokine receptor-4 targeted PET/CT with 68 Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT

PL00007：Sarcomililate A, an Unusual Diterpenoid with Tricyclo[11.3.0.02,16]hexadecane Carbon Skeleton, and Its Potential Biogenetic Precursors from the Hainan Soft Coral Sarcophyton mililatensis

PL00008：Fibroblast activation protein targeted PET/CT with 68Ga-FAPI for imaging IgG4-related disease: comparison to 18F-FDG PET/CT

PL00009：Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with[68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG

PL00010：RIPK3–MLKL–Mediated Neutrophil Death Requires Concurrent Activation of Fibroblast Activation Protein-α

PL00011：Pre-clinical Evaluation of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 For Imaging of Insulinoma

PL00012：ISP and PAP4 peptides promote motor functional recovery after peripheral nerve injury

PL00013：Chemokine Receptor 4–Targeted 68 Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Comparison to 18F-FDG PET/CT

PL00014：Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

PL00015：Preparation of [177Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies

PL00016：68Ga-FAPI PET/CT for Rheumatoid Arthritis: A Prospective Study

PL00017：[68 Ga]Ga-FAPI-04 PET/CT may be a predictor for early treatment response in rheumatoid arthritis

PL00018：Different extramedullary disease shown in chemokine receptor 4 targeted PET/CT with [68Ga]Ga-pentixafor in patients with Waldenström macroglobulinemia and smoldering disease

PL00019：68Ga-FAPI and 18F-NaF PET/CT in psoriatic arthritis: a lcomparative study

PL00020：Head-to-Head Comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT for the Assessment of Crohn’s Disease

PL00021：Differences in Fibroinflammatory Activity Shown on 68Ga-FAPI-04 and 18F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease

PL00022：Accurate de novo design of membrane-traversing macrocycles

PL00023：Common fibrillar spines of amyloid- and human islet amyloid polypeptide revealed bymicroelectron diffraction and structure-based inhibitors

PL00024：Very-long-chain fatty acids induce glial-derived sphingosine-1-phosphate synthesis, secretion, and neuroinflammation

PL00025：Designer and natural peptide toxin blockers of the KcsA potassium channel identified by phage display

PL00026：Molecular determinants of inhibition of the human proton channel hHv1 by the designer peptide C6 and a bivalent derivative

PL00027：Role of human Hv1 channels in sperm capacitation and white blood cell respiratory burst established by a designed peptide inhibitor